Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies

Neurology and Therapy(2021)10.1007/s40120-021-00286-9Source: DataRank Database

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies is a research paper published in Neurology and Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: goldTopics (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Marwan N. Sabbagh ORCID,Babak Tousi ORCID

Live enrichment

PubMed:34643892 PMC:PMC8511610 OpenAlex:https://openalex.org/W3205081227

NIA NIH HHS

Grant: P20 AG068053

NIA NIH HHS

Grant: R01 AG059008

NIGMS NIH HHS

Grant: P20 GM109025

National Institutes of Health

Grant: 5P20GM109025-03

COBRE GRANT

National Institutes of Health

Grant: 5P20AG068053-03

Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC)

National Institutes of Health

Grant: 1R01AG059008-01

Assessment of lenalidomide to treat Alzheimer's disease

goldLicense: cc-by-nc

journalhttps://link.springer.com/content/pdf/10.1007/s40120-021-00286-9.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40120-021-00286-9.pdf

publisherhttps://link.springer.com/article/10.1007/s40120-021-00286-9/fulltext.html

journalhttps://doi.org/10.1007/s40120-021-00286-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34643892

Fields of Study

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchHealth, Environment, Cognitive Aging03 medical and health sciences0302 clinical medicine

Keywords

Monoclonal antibodyMedicineNeurologyAmyloid (mycology)AntibodyAlzheimer's diseaseTransition (genetics)DiseaseNeurosciencePathologyImmunologyBiologyPsychiatryBiochemistryMonoclonal antibodiesAlzheimer’s diseaseMild Cognitive ImpairmentDisease-modifying TreatmentsAducanumabEditorial

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies

FAIR Checklist

Authors (2)

Funding (6 grants)

Open Access

Topics

Annotations (Europe PMC)